Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations - Trial NCT06299371
Access comprehensive clinical trial information for NCT06299371 through Pure Global AI's free database. This Phase 2 trial is sponsored by Liaoning Tumor Hospital & Institute and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Liaoning Tumor Hospital & Institute
Timeline & Enrollment
Phase 2
Apr 15, 2024
Apr 15, 2029
Primary Outcome
Pathological complete response rate
Summary
This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab
 in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as
 neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06299371
Non-Device Trial